<DOC>
	<DOCNO>NCT00005012</DOCNO>
	<brief_summary>The purpose study see effective give PEG-Intron ( PEG-IFN ) HIV-infected patient well current anti-HIV drug combination ( HAART ) .</brief_summary>
	<brief_title>Safety Effectiveness PEG-Intron HIV-Infected Patients</brief_title>
	<detailed_description>At entry , patient undergo HIV genotypic/phenotypic analysis . Patients continue current antiretroviral regimen randomize receive one four dose PEG-IFN PEG-IFN placebo administer subcutaneously per week result HIV genotyping/phenotyping available ( approximately 4 week ) . Patients respond 0.5 log great decrease HIV RNA Week 4 optimize HAART add ongoing PEG-IFN regimen follow 24 week observational study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Have HIV level 2000 copies/ml . Have fail current HAART ( significant increase HIV level HAART ) . Have CD4 cell count great 200 cells/microL . Have 6 month HAART . Have current HAART least 6 week . Agree use effective method birth control study . Exclusion Criteria Patients eligible study : Have history serious mental disorder . Are allergic interferon . Are pregnant breastfeeding . Are take certain medication ribavirin , hydroxyurea , ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Lymphocyte Transformation</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Virus Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>